Tesamorelin


Available sizes: 5 mg, 10 mg, 20 mg
Tesamorelin is the full 44-residue GHRH sequence with a trans-3-hexenoyl group on the N-terminal tyrosine. The modification blocks the degradation route that limits native GHRH while leaving receptor binding intact.
It was developed to approval and is prescribed for HIV-associated lipodystrophy, which means its evidence base includes randomised controlled trials with imaging endpoints rather than only preclinical work.
The registration trials used CT-measured visceral adipose tissue as a primary endpoint. That produced something unusual: quantitative human data distinguishing visceral from subcutaneous compartments under GHRH receptor stimulation. Research areas follow from it:
Visceral adipose tissue and its regulation through the somatotropic axis
HIV-associated lipodystrophy, the approved indication
Non-alcoholic fatty liver disease, where hepatic fat has been a subsequent endpoint
Cognitive measures in ageing, a smaller secondary literature
GHRH receptor pharmacology, with tesamorelin as the clinically characterised reference
Sermorelin and CJC-1295 are the other GHRH analogues here, differing in how they solve the stability problem. IGF-1 LR3 is the downstream mediator.
Certificates of Analysis are published for tested products and batches. A certificate is a batch-specific record: it reports what was measured, by which method, on a stated date, against a batch identifier. It is evidence about the sample analysed at the time of analysis, and it is silent on attributes it does not list and on what has happened to the material since.
The batch number is the field that connects the document to a physical vial. Where the identifier on a vial does not appear on a certificate, the certificate does not describe that vial, however thorough the analysis behind it was. Batch records can be searched directly, and the guides below explain what each field establishes and what it does not.
Supplied for laboratory research use only. Not for human or veterinary use.